Current Patent Protection for Cosentyx
Cosentyx (secukinumab), made by Novartis, treats psoriasis, psoriatic arthritis, and ankylosing spondylitis. Its main U.S. patents expire in 2032, blocking generic or biosimilar entry until then.[1] The biologic nature of Cosentyx means competitors must develop biosimilars, which face additional FDA approval hurdles beyond patent expiry.
When Does the Key Patent Expire?
The primary composition-of-matter patent (US 7,968,761) for secukinumab expires February 23, 2032. Related patents on formulations and methods extend protection to 2034 in some cases, but the core patent sets the earliest generic launch window.[1][2]
Biosimilar Challenges and Timelines
No biosimilars are approved yet. The FDA's abbreviated pathway requires proving similarity to the reference product, often taking 8-10 years post-application. Potential challengers like Alvotech and Formycon have filed, but litigation could delay launches past 2032.[1][3] In Europe, patent expiry is similar (2033), with no approved biosimilars as of now.
Ongoing Litigation and Challenges
Novartis faces Paragraph IV challenges from multiple companies seeking early entry. A key case involves Alvotech's BLA filing; settlement or court rulings could shift timelines to 2030-2033. Track updates on DrugPatentWatch for settlements.[1]
Factors That Could Speed Up Generics
- Settlements: Novartis may license biosimilars for launch at patent expiry or slightly before.
- Hatch-Waxman Exclusivity: 12-year biologic exclusivity ended in 2027; no further barriers there.
- International Differences: Canada and Japan have earlier expiries (2029-2030), potentially allowing supply rerouting.[1][2]
Price Impact of Generic Entry
Biosimilars could cut Cosentyx's list price (around $6,000/month) by 20-40%, based on patterns with Humira and Stelara biosimilars.[3]
[1]: DrugPatentWatch.com - Cosentyx Patents
[2]: FDA Orange Book - Secukinumab
[3]: FDA Biosimilar Approvals Tracker